Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 10—October 2014
Dispatch

Treatment of Giardiasis after Nonresponse to Nitroimidazole

Eli Schwartz, Tamar Lachish, and Eli SchwartzComments to Author 
Author affiliations: The Chaim Sheba Medical Center and the Center for Geographic Medicine, Tel Hashomer,
Israel (E. Meltzer, E. Schwartz); Tel Aviv University, Tel Aviv, Israel (E. Meltzer, E. Schwartz); Shaare Zedek Medical Center, Jerusalem, Israel (T. Lachish)

Main Article

Table 2

Reports on management of giardiasis nonresponsive to nitroimidazole treatment worldwide, 1962–2013*

Country and publication year No. cases No. patients who visited developing
countries No. cured/no. treated (% cured), by treatment type
Alb Paromo Nitaz Alb + nitroimid Quin Quin + nitroimid Paromo + nitroimid
Israel, 2014 (this study) 12 10 3/9 (33.3) 1/1 (100) 1/4 (25.0) 1/2 (50.0) 2/2 (100)
Spain, 2014 3 3 3/3 (100.0)
Spain, 2013 14 14 0/2 0/4 14/14 (100)
Spain, 2010 10 8 0/2 0/3 1/1 (100) 4/4 (100) 2/2 (100)
Norway, 2008 38 0 3/6 (50.0) 30/38 (78.9) 3/3 (100)
United States, 2001 5 0 0/2 1/3 (33.3)† 5/5 (100)
France, 2000 3 0 1/3 (33.3)
Italy, 1995 20 0 2/10 (20.0) 9/10 (90.0)
Single case reports, 1962–2008‡
5
1
0/4

1/1 (100)
1/2 (50.0)
0/2
2/2 (100)

Total 110 36 6/32 (18.7) 5/17 (29.4) 2/5 (40.0) 42/53 (79.2)§ 19/21 (90.5) 14/14 (100) 2/2 (100)

*Complete reference information available in the online Technical Appendix (http://wwwnc.cdc.gov/EID/article/20/10/14-0073-Techapp1.pdf). Alb, albendazole; nitaz, nitazoxanide; nitroimid, nitroimidazole; paromo, paromomycin; quin, quinacrine; –, drug not used.
†Used in combination with bacitracin.
‡Single case reports from France, Switzerland, Canada, Saudi Arabia, and Thailand.
§p<0.001 by Fisher exact test for comparison with alb monotherapy.

Main Article

Page created: September 22, 2014
Page updated: September 22, 2014
Page reviewed: September 22, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external